RESTEM is a leading clinical-stage biotechnology company focused ... San Antonio Breast Cancer Symposium · NEWS · NATION · REGIONS · BUSINESS · WORLD.
News
- RESTEM Announces First-Patient-Dosed in the Phase 1/2a Study of Restem-L ... - The Manila Times
- Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients ...
These data will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS), December 9-12. ... Crescent, Kelun-Biotech Swap Therapies in ADC- ...
- CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple ... - BioSpace
... San Antonio Breast Cancer Symposium (SABCS). The poster (ID: PS5-02-30) ... Crescent, Kelun-Biotech Swap Therapies in ADC-Bispecific Deal Worth Up To ...
- Mount Sinai Showcases Breast Cancer Research at the 2025 San Antonio Breast Cancer ...
... San Antonio Breast Cancer Symposium (SABCS), Tuesday-Friday, December 9 ... Its Graduate School of Biomedical Sciences offers 13 degree ...
- SABCS 2025: REVEAL GENOMICS Presents Major Advance in Predicting Brain Metastasis ...
BARCELONA, Spain--(BUSINESS WIRE)--REVEAL GENOMICS, S.L., a Barcelona-based biotechnology ... San Antonio Breast Cancer Symposium (SABCS) 2025, held ...